Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

of this product franchise.

-- Sales of Sepra(R) products continued to be strong, rising 32 percent to

$30.6 million in the first quarter from $23.1 million in the same

quarter a year ago. The expanded U.S. sales force for Seprafilm(R)

adhesion barrier is reaching a broader range of physicians and helping

drive the product's growth in gynecologic and colorectal surgery.

Future growth of the product in C-section procedures and trauma

surgeries is expected.

-- First-quarter revenue for the Genetics business increased 12 percent to

$74.3 million from $66.2 million, fueled substantially by a higher

volume of reproductive diagnostic testing. The profitability of the

Genetics business is also increasing through improvements in operating

efficiencies, while Genzyme continues to invest in additional

information technology and infrastructure to strengthen the competitive

advantages the business has created. Genzyme Genetics recently

launched carrier and prenatal diagnostic testing for spinal muscular

atrophy, the most common inherited cause of infant mortality. These

tests are expected to support continued profitable growth in subsequent

quarters.

-- Oncology revenue increased 29 percent in the first quarter to $29.0

million from $22.4 million. This growth primarily reflects the

addition of European sales of Clolar, which Genzyme began recording

following its acquisition of Bioenvision Inc. late last year. Genzyme

is working to introduce Clolar worldwide through its global commercial

and regulatory organization. Oncology revenue also reflects growing

first-line use of Campath(R) (alemtuzumab) in the treatment of patients

with B-cell chronic lymphocytic leukemia.

Late-State Development Programs

Genzyme continues to make strong prog
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Analyzing a puzzling multisystem disorder in ... syndrome, shedding light on key biological processes during ... to help caregivers manage the disorder, and may ... "This syndrome illuminates a very important pathway in ... controls many other genes," said study leader ...
(Date:3/2/2015)... 2, 2015 Editor Note: For ...   Moments ago, Analysts Review released new research ... (NASDAQ: SSH ), Synergetics USA ... ELOS ), Spectranetics (NASDAQ: SPNC ), ... a single unified platform for investors, to hear about what ...
(Date:3/2/2015)... 2015 Outside GC, the leading provider ... addition of Debbie Casey as a member of the ... space. , Debbie has spent over 20 ... Fresenius Medical Care North America in both legal and ... to work with Outside GC’s growing list of healthcare ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
Breaking Biology Technology:New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Outside GC Expands Healthcare Team 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... Audio Webcast Tuesday, September 11, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Bear ... 11, 2007 at 10:30 a.m. Eastern Time (ET),/7:30 a.m. ... may be accessed on the Company,s website at, http://www.neurocrine.com ...
... that NKTR-118 Shows Promise for the Treatment of Opioid ... ... Calif., Sept. 10 Nektar,Therapeutics (Nasdaq: NKTR ) presented ... San Francisco, California from a,Phase 1 trial of NKTR-118 (oral ...
... BioStorage Technologies, Inc.,(BST) announced that it has ... (IPL) to purchase electricity generated by 100 percent,renewable ... By offsetting the use of fossil-fueled power generation, ... carbon-neutral by 2009. BST becomes the third-largest ...
Cached Biology Technology:Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 3Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 4Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 5BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 3BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 4
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... life in higher animals, vitamin D, once linked to only ... as a major player in contributing to overall human health, ... on vitamin D. In a paper published in the ... Nutrition , Norman identifies vitamin D,s potential for contributions ...
... Carolina State University is leading to a new kind ... from freshwater ponds, instead of from the sea. ... crabs look and taste just like their ocean-raised brethren. ... at historic lows since 2000. Dr. Dave Eggleston, director ...
... develop sustainable energy systems while reducing the harmful ... phased out over the next century. This optimistic ... technologies such as biomimetics and Dye Sensitized solar ... or storing solar energy, and nanocatalysis develops efficient ...
Cached Biology News:Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Turning freshwater farm ponds into crab farms 2Europe rallies behind nanotechnology to wean world from fossil fuels 2Europe rallies behind nanotechnology to wean world from fossil fuels 3Europe rallies behind nanotechnology to wean world from fossil fuels 4
...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
Biology Products: